Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Conditions
Brief summary
This clinical trial evaluates changes in cardiac (heart) function during stress echocardiography to screen for chemically induced cardiotoxicity in cancer patients at a high risk for developing heart failure. Some chemotherapeutic agents to treat certain types of cancers can induce cardiac dysfunction and heart failure. Currently there is no validated means of predicting which patients will go on to develop cardiac toxicity and heart failure following treatment with chemotherapeutic agents. Stress echocardiography is a test that uses ultrasound imaging to show how well the heart muscle is working to pump blood to the body during low intensity exercise. Stress echocardiography prior to and during cancer treatment may help doctors find cancer therapeutic related cardiac dysfunction sooner when it may be easier to treat.
Detailed description
PRIMARY OBJECTIVES: I. To determine whether changes in the following parameters of cardiac function at rest or with low intensity exercise occur following (1) treatment with cancer therapeutics or (2) cardiac rehabilitation: Ia. 2-Dimensional (2D) and 3-dimensional (3D) left ventricular (LV) longitudinal strain and strain rate; Ib. Right ventricular (RV) longitudinal strain and strain rate; Ic. LV circumferential and radial strain and strain rate; Id. 2D and 3D wall motion; Ie. 2D and 3D volumetric left ventricular ejection fraction (LVEF); If. Mitral valve inflow velocities (E, A) and mitral annular tissue Doppler (e', a'); Ig. Tricuspid tissue velocities and tricuspid annular plane systolic excursion (TAPSE). SECONDARY OBJECTIVES: I. To determine whether changes after treatment with cancer therapeutics or a period of cardiac rehabilitation in any of the aforementioned parameters of cardiac function with low intensity exercise: Ia. Occur before changes in resting strain or resting LVEF; Ib. Predict future reductions in LVEF (cardiotoxicity) or in the case of cardiac rehabilitation, prevention of LVEF decrease; Ic. Predict the development of clinical heart failure. OUTLINE: Participants are assigned to 1 of 2 groups. GROUP I (CASE): Patients choose to undergo either a resting echocardiography performed before and after delivery of a cancer therapeutic agent and months 3, 6, 9 and 12 or up to 5 low intensity stress echocardiography over 25 minutes performed depending on where they are at in the course of their cancer therapy and/or cardiac rehabilitation program at baseline and/or months 3, 6, 9 and 12 after starting cancer therapy. GROUP II (CONTROL): Participants undergo low intensity stress echocardiography over 25 minutes at baseline and may undergo a second one at least 24 hours later. After completion of study intervention, patients in Group 1 are followed up at 2, 5, and 10 years.
Interventions
PROCEDUREEchocardiography
Undergo resting echocardiography
OTHERElectronic Health Record Review
Ancillary studies
OTHERQuestionnaire Administration
Ancillary studies
PROCEDUREStress Echocardiography
Undergo stress echocardiography
Sponsors
Mayo Clinic
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Current or previous diagnosis of solid organ cancers (breast, non-small cell lung, rectal, renal, hepatic cancer, metastatic melanoma, sarcoma) or hematological disease (lymphoma, leukemia, multiple myeloma, monoclonal gammopathy of undetermined significance \[MGUS\]) * Age \>= 18 years at study enrollment * Plan to receive, or history of having received, chemotherapy (anthracycline, alkylating agent \[cyclophosphamide, ifosfamide\], and/or antimicrotubule agent \[docetaxel, paclitaxel\]) with or without specific targeted therapies; * Anti-HER2 targeted therapies (trastuzumab, pertuzumab) * Vascular endothelial growth factor (VEGF) inhibitors (bevacizumab, sunitinib, sorafenib, pazopanib, axitinib, vandetanib) * Immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab) * Plan to undergo conditioning chemotherapy for bone marrow transplantation (autologous/allogeneic)
Exclusion criteria
* Coronary artery disease * Significant (more than mild) valvular heart disease * Pre-existing heart failure * Pre-existing cardiomyopathy * Musculoskeletal or neurologic abnormality prohibiting low intensity exercise on a stationary bicycle * Severe pulmonary disease limiting ability to perform low intensity exercise on a stationary bicycle
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in cardiac function with low intensity exercise in cancer patients | Baseline to 12 months | Resting echocardiography will be performed immediately before and after patient receives cancer therapeutic treatment. Up to five sessions of low intensity stress echocardiograms will be performed during the course of the study depending on where they are in the course of cancer therapy and/or cardiac rehabilitation program at study enrollment. Patients may opt to change from low intensity echocardiogram to resting echocardiogram during the course of the study. |
| Changes in cardiac function with low intensity exercise in cancer patients after treatment with cancer therapeutics. | Baseline to 12 months | Resting echocardiography will be performed immediately before and after patient receives cancer therapeutic treatment. Up to five sessions of low intensity stress echocardiograms will be performed by during the course of the study depending on where they are in the course of cancer therapy and/or cardiac rehabilitation program at study enrollment. Patients may opt to change from low intensity echocardiogram to resting echocardiogram during the course of the study. D |
| Changes in cardiac function with low intensity exercise in cancer patients after a period of cardiac rehabilitation. | Baseline to 12 months | Resting echocardiography will be performed immediately before and after patient receives cancer therapeutic treatment. Up to five sessions of low intensity stress echocardiograms will be performed by during the course of the study depending on where they are in the course of cancer therapy and/or cardiac rehabilitation program at study enrollment. Patients may opt to change from low intensity echocardiogram to resting echocardiogram during the course of the study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reductions in left ventricular ejection fraction (LVEF) | Up to 10 years | Data will be collected from chart reviews and patient surveys. Predictors of reductions in LVEF will be assessed using linear regression and multiple linear regression analyses. A p-value \< 0.05 will define significance. Cancer Therapeutics-Related Cardiac Dysfunction will be defined as per recent guidelines as a drop in LVEF of \> 10% to \< 53%. |
| Reductions in onset of clinical heart failure | Up to 10 years | Data will be collected from chart reviews and patient surveys. Predictors of reductions in heart failure will be assessed using linear regression and multiple linear regression analyses. A p-value \< 0.05 will define significance. Heart failure will be defined as a diagnosis made by one of the patients treating physicians. |
Countries
United States
Outcome results
None listed